Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice
Seminars in Arthritis and Rheumatism, Volume 49, No. 1, Year 2019
Notification
URL copied to clipboard!
Description
Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical practice Methods: Observational, open-label multicenter study from 40 national referral centers of GCA patients treated with TCZ due to inefficacy or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants, glucocorticoid-sparing effect, prolonged remission and relapses. A comparative study was performed: (a) TCZ route (SC vs. IV); (b) GCA duration (≤6 vs. >6 months); (c) serious infections (with or without); (d) ≤15 vs. >15 mg/day at TCZ onset. Results: 134 patients; mean age, 73.0 ± 8.8 years. TCZ was started after a median [IQR] time from GCA diagnosis of 13.5 [5.0–33.5] months. Ninety-eight (73.1%) patients had received immunosuppressive agents. After 1 month of TCZ 93.9% experienced clinical improvement. Reduction of CRP from 1.7 [0.4–3.2] to 0.11 [0.05–0.5] mg/dL (p < 0.0001), ESR from 33 [14.5–61] to 6 [2–12] mm/1st hour (p < 0.0001) and decrease in patients with anemia from 16.4% to 3.8% (p < 0.0001) were observed. Regardless of administration route or disease duration, clinical improvement leading to remission at 6, 12, 18, 24 months was observed in 55.5%, 70.4%, 69.2% and 90% of patients. Most relevant adverse side-effect was serious infections (10.6/100 patients-year), associated with higher doses of prednisone during the first three months of therapy. Conclusion: In clinical practice, TCZ yields a rapid and maintained improvement of refractory GCA. Serious infections appear to be higher than in clinical trials. © 2019 Elsevier Inc.
Authors & Co-Authors
Calderon-Goercke, Mónica
Spain, Santander
Universidad de Cantabria
Loricera, Javier
Spain, Santander
Universidad de Cantabria
Castañeda, Santos
Spain, Madrid
Hospital Universitario de la Princesa
Moriano, Clara
Spain, Leon
Complejo Asistencial Universitario de León
Romero-Yuste, Susana María
Unknown Affiliation
Narváez, Javier A.
Spain, Barcelona
Hospital Universitari de Bellvitge
Álvarez Rivas, Noelia
Spain, Lugo
Hospital Universitario Lucus Augusti
Galisteo, Carlos
Spain, Barcelona
Hospital Parc Taulí
Sivera, Francisca
Unknown Affiliation
Navarro, Francisco José
Spain, Elche
Hospital General Universitario de Elche
Raya Álvarez, Enriqué G.
Spain, Granada
Hospital Universitario San Cecilio
Galíndez Agirregoikoa, Eva
Spain, Bilbao
Osakidetza, Basurto University Hospital
Solans-Laqué, Roser
Spain, Barcelona
Hospital Universitari Vall D'hebron
Conesa, Arantxa
Unknown Affiliation
Palmou, Natalia
Spain, Santander
Universidad de Cantabria
Calvo-Río, Vanesa
Spain, Santander
Universidad de Cantabria
Prieto-Pena, Diana
Spain, Santander
Universidad de Cantabria
González-Vela, María Carmen
Spain, Santander
Universidad de Cantabria
Corrales, Alfonso F.
Spain, Santander
Universidad de Cantabria
Aurrecoechea, Elena
Spain, Torrelavega
Hospital Sierrallana
Herńandez, José L.
Spain, Santander
Universidad de Cantabria
González-Gay, Miguel Ángel
Spain, Santander
Universidad de Cantabria
Blanco-Alonso, Ricardo
Spain, Santander
Universidad de Cantabria
Statistics
Citations: 63
Authors: 23
Affiliations: 32
Identifiers
Doi:
10.1016/j.semarthrit.2019.01.003
ISSN:
00490172